Payment overview · 2025
General Payments
$229.30
12 reported records · 9 companies
Healthcare provider profile · identity verified
David Mckenna, PA-C
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · SENECA, SC · NPI 1215538913
Verified facts
What the public records show
CMS Open Payments records show David Mckenna, PA-C received $229.30 in general payments during 2025 across 12 reported records.
Lilly USA, LLC accounted for 20.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.89 | 20.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.80 | 18.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $31.59 | 13.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.61 | 10.3% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.52 | 8.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.55 | 7.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $17.03 | 7.4% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.84 | 6.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.47 | 6.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $229.30 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.89 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.13 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $17.03 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.66 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $15.84 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 130 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 60 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 126 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
130 | 30 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
126 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
60 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 264 | 105 |
| Ramipril | Ramipril | 192 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 173 | 68 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 169 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 164 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 155 | 63 |
| Omeprazole | Omeprazole | 137 | 53 |
| Farxiga | Dapagliflozin Propanediol | 130 | 30 |
| Alprazolam | Alprazolam | 129 | 27 |
| Metformin Hcl | Metformin Hcl | 127 | 53 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 126 | 35 |
| Gabapentin | Gabapentin | 119 | 43 |
| Carvedilol | Carvedilol | 108 | 40 |
| Ozempic | Semaglutide | 105 | 32 |
| Meloxicam | Meloxicam | 95 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 93 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 91 | 40 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 88 | 36 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 87 | 27 |
| Prednisone | Prednisone | 84 | 75 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 25 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 31 |
| Methylprednisolone | Methylprednisolone | 77 | 66 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 31 |
| Ezetimibe | Ezetimibe | 75 | 33 |
| Tramadol Hcl | Tramadol Hcl | 68 | 22 |
| Montelukast Sodium | Montelukast Sodium | 66 | 32 |
| Lisinopril | Lisinopril | 65 | 26 |
| Furosemide | Furosemide | 64 | 25 |
| Mounjaro | Tirzepatide | 60 | 14 |
| Azithromycin | Azithromycin | 57 | 53 |
| Famotidine | Famotidine | 57 | 25 |
| Losartan Potassium | Losartan Potassium | 57 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 57 | 28 |
| Eliquis | Apixaban | 56 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 53 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 52 | 23 |
| Ondansetron Odt | Ondansetron | 51 | 24 |
| Potassium Chloride | Potassium Chloride | 49 | 19 |
| Celecoxib | Celecoxib | 48 | 19 |
| Finasteride | Finasteride | 48 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 48 | 11 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 45 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 39 |
| Allopurinol | Allopurinol | 41 | 14 |
| Trazodone Hcl | Trazodone Hcl | 41 | 17 |
| Clonazepam | Clonazepam | 38 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 37 | 15 |
| Cephalexin | Cephalexin | 36 | 29 |
| Repatha Sureclick | Evolocumab | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 34 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 12 |
| Jardiance | Empagliflozin | 33 | 11 |
| Rybelsus | Semaglutide | 33 | 11 |
| Sucralfate | Sucralfate | 32 | suppressed |
| Simvastatin | Simvastatin | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 23 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 28 | 15 |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | 12 |
| Nystatin | Nystatin | 25 | 12 |
| Alendronate Sodium | Alendronate Sodium | 24 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 24 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | 14 |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Pregabalin | Pregabalin | 22 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Linzess | Linaclotide | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 16 |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Valsartan | Valsartan | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | 11 |
| Folic Acid | Folic Acid | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $229.30 · 12 records | Lilly USA, LLC | BREZTRI, CAPLYTA, FANAPT, FARXIGA, GVOKE HYPOPEN, HETLIOZ, INSPIRE, LEQVIO, MOUNJARO, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error